Klotho Neurosciences to Present at the Biotech Showcase 2026

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) announced that CEO Dr. Joseph Sinkule will present at the Biotech Showcase 2026 in San Francisco on January 13, 2026 at 11:30 AM PT. The event runs January 12–14, 2026 at the Hilton San Francisco Union Square. Company management will be available for one-on-one investor and partner meetings; meeting requests can be sent to ir@klothoneurosciences.com.

News Market Reaction – KLTO

+1.21%

1 alert

+1.21% News Effect

+$312K Valuation Impact

$26.11M Market Cap

0.1x Rel. Volume

On the day this news was published, KLTO gained 1.21%, reflecting a mild positive market reaction. This price movement added approximately $312K to the company's valuation, bringing the market cap to $26.11M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Klotho’s participation at Biotech Showcase 2026 and its availability fo...

Analysis

This announcement highlights Klotho’s participation at Biotech Showcase 2026 and its availability for one-on-one meetings with investors and partners on January 13, 2026. Recent history shows a pattern of conference appearances, awards, and strategic decisions shaping the company’s visibility. Regulatory filings underscore ongoing net losses and dependence on financing, so investors may focus on whether such events translate into partnerships, funding, or progress in Klotho-based therapeutic programs over time.

Key Figures

Q3 2025 net loss: $2,895,585 9M 2025 net loss: $9,222,798 Cash & cash equivalents: $7,348,034 +5 more

8 metrics

Q3 2025 net loss $2,895,585 Quarter ended September 30, 2025 (10-Q)

9M 2025 net loss $9,222,798 Nine months ended September 30, 2025 (10-Q)

Cash & cash equivalents $7,348,034 Balance at September 30, 2025 (10-Q)

ATM program size $50,000,000 At-the-market offering program disclosed in Q3 2025 10-Q

Warrants exercised 11.0 million Exercises in 2025 for $11.4M gross proceeds (10-Q)

Warrant proceeds $11.4 million Gross proceeds from warrant exercises during 2025 (10-Q)

S-1 resale shares 35,000,000 shares Common stock covered by IPO registration statement (S-1)

Series C purchase price $15,000,000 Aggregate purchase price for Series C Convertible Preferred (S-1)

Historical Context

5 past events · Latest: Sep 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 08	Scientific conference	Positive	+3.3%	CEO and advisors presenting Klotho-based neurodegenerative research at inaugural seminar.
Sep 30	LOI & partnership	Positive	-4.2%	LOI to buy Turn Biotechnologies assets plus a cited $300M global pharma partnership.
Oct 07	Strategic refocus	Positive	+14.3%	Letting Turn LOI expire to concentrate on Klotho anti-aging protein pipeline.
Oct 16	Investor conference	Neutral	-6.3%	Management attending Longevity Biotech 2025 with one-on-one investor meeting availability.
Nov 07	Industry award	Positive	-3.2%	Winning 2025 Cell Therapy Innovation of the Year for Klotho-based gene and cell work.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been promotional or strategic, with mixed price follow-through: awards and partnership headlines sometimes saw negative reactions, while a strategic pivot away from an LOI drew a strong positive move.

Recent Company History

Over the last few months, Klotho has highlighted conferences, awards, and strategic shifts. On Sep 8, 2025, a scientific conference appearance with Klotho gene therapy presentations saw a modest gain. A Sep 30, 2025 LOI tied to a $300 million pharma partnership was followed by a decline, while the Oct 7, 2025 decision to let that LOI expire and refocus on core Klotho programs coincided with a strong rise. Subsequent conference attendance in October 2025 and a November 7, 2025 innovation award drew negative price reactions. Today’s Biotech Showcase appearance continues the pattern of visibility-focused news and investor meeting opportunities.

Key Terms

at-the-market program, ipo registration statement, form s-8, reoffer prospectus, +4 more

8 terms

at-the-market program financial

"the company set up an at-the-market program of up to $50,000,000"

An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.

ipo registration statement regulatory

"Files IPO Registration Statement"

An IPO registration statement is the formal filing a company submits to securities regulators that describes its business, financial performance, legal issues and the risks of buying its shares before those shares are offered to the public. Think of it as a combined product brochure and instruction manual for prospective investors: it provides the facts required to evaluate value and risk, and its clarity and disclosures influence investor confidence, pricing and the timing of the offering.

form s-8 regulatory

"filed a Form S-8 to register 1,588,691 shares of common stock"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

reoffer prospectus regulatory

"The filing also includes a Reoffer Prospectus covering the potential resale"

A reoffer prospectus is the final sales document underwriters use when they put newly issued securities up for public sale, listing the exact price, number of shares, and key terms. Think of it like a detailed product label or brochure for an offering: it tells investors what is being sold, how much it costs, and the main risks, so buyers can compare deals and make informed investment choices.

series c convertible preferred stock financial

"shares issuable upon conversion of newly created Series C Convertible Preferred Stock"

Series C convertible preferred stock is a class of investment shares issued in a later private financing round that combine safety and upside: they usually pay ahead of ordinary shares if a company pays dividends or is sold, but can be converted into common stock to share in future growth. For investors this acts like a VIP ticket with a safety net—offering priority protection while preserving the option to participate in a successful exit.

form 4 regulatory

"[Form 4] Klotho Neurosciences, Inc. Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

going concern financial

"notes substantial doubt about the ability to continue as a going concern"

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

nasdaq minimum bid price deficiency regulatory

"discloses a Nasdaq minimum bid price deficiency with a compliance window"

Nasdaq minimum bid price deficiency is when a listed stock consistently trades below the exchange’s required minimum share price (commonly $1) for a set period, meaning the company has not met Nasdaq’s rule. Investors should care because persistent deficiency can trigger warnings and eventual delisting, similar to a store losing its license if it fails safety inspections, which can reduce liquidity, limit trading options and lower shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company"), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting at the 2026 Biotech Showcase in San Francisco on January 13, 2026 at 11:30AM PT.  The Biotech Showcase is to be held January 12-14, 2026 at the Hilton San Francisco Union Square.

At the event, the Company will be available for one-on-one meetings with investors and potential partners. To request a meeting, please contact ir@klothoneurosciences.com.

About Klotho Neurosciences, Inc.  

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Contact and Corporate Communications:

Jeffrey LeBlanc, CFO
ir@klothoneuro.com

Website: www.klothoneuro.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-to-present-at-the-biotech-showcase-2026-302655910.html

SOURCE Klotho Neurosciences, Inc.

FAQ

When will Klotho Neurosciences (KLTO) present at Biotech Showcase 2026?

CEO Dr. Joseph Sinkule will present on January 13, 2026 at 11:30 AM PT.

Where is the Biotech Showcase 2026 where KLTO will present?

The conference is at the Hilton San Francisco Union Square in San Francisco, January 12–14, 2026.

How can investors request a one-on-one meeting with KLTO at Biotech Showcase 2026?

Investors can request meetings by emailing ir@klothoneurosciences.com.

Will Klotho Neurosciences management be available for partner meetings at Biotech Showcase 2026?

Yes, company management will be available for one-on-one meetings with investors and potential partners during the event.

What is the ticker symbol for Klotho Neurosciences mentioned in the Biotech Showcase announcement?

The company trades under the ticker KLTO on Nasdaq.